KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $166.4 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.71% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.7 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $166.4 million for FY2024, which is 1.35% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) is $166.4 million, which was up 1.35% from $164.2 million recorded in FY2023.
  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $166.4 million during FY2024, with a 5-year trough of $160.0 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $164.2 million (2023), whereas its average is $164.3 million.
  • Data for Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 3.91% (in 2020) over the last 5 years.
  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $160.0 million in 2020, then rose by 0.44% to $160.8 million in 2021, then rose by 0.92% to $162.2 million in 2022, then increased by 1.20% to $164.2 million in 2023, then increased by 1.35% to $166.4 million in 2024.